Press Release Archive

October 25, 2011 - Peggy Fleming and the Makers of Robitussin® Provide Relief this Cold and Flu Season with a Simple Question: "Does Your Last Name Sound Contagious?"

(BUSINESS WIRE)--This week, Robitussin® marked the start of another cold and flu season by shaking up the most contagious months of the calendar year for America’s “sick but can’t stop” sufferers with the launch of the Simple Acts of Relief program. To kick-off the launch of the program, Robitussin® has teamed up with iconic Olympic and World ice skating champion and sports commentator, Peggy Fleming. As the “simplest” act of relief, the

October 25, 2011 - Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search

(BUSINESS WIRE)--The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat

October 24, 2011 - Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACR

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s specialty care leadership team at an analyst and investor meeting on Sunday, November 6, 2011 at 6:30 p.m. Central Standard Time, in connection with the annual meeting of the American College of Rheumatology (ACR). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “

October 20, 2011 - Additional Data From Pfizer’s Prevnar 13® Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the

October 17, 2011 - Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and India

(BUSINESS WIRE)--Pfizer Animal Health and The Resource Foundation announced today the expansion of a comprehensive education and training program to increase the capacity, productivity and quality of life of rural farmers in eight Latin American countries. Plans call for tailoring the program to the needs of rural communities in India. The agreement was guided by results of a decade-long collaboration also announced today. Pfizer

October 13, 2011 - Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for Seniors

((BUSINESS WIRE)--LOUISVILLE, Ky

October 5, 2011 - Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor

(BUSINESS WIRE)--Pfizer Inc. announced today an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer. Under the terms of the agreement, Puma will assume sole responsibility for global development and commercialization of neratinib. Pfizer

October 3, 2011 - Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our

September 30, 2011 - Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony

(BUSINESS WIRE)--The Prix Galien USA committee recognized excellence in scientific innovation that improves the state of human health last night during the fifth annual Prix Galien Awards Gala. The Pro Bono Humanum Award and the Prix Galien USA 2011 Awards for best biotechnology product and best pharmaceutical agent were presented at a ceremony held at the Museum of Natural History in New York City. The Prix Galien USA 2011 Award

September 29, 2011 - Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems. The primary analysis of this double-

September 28, 2011 - The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the National Association of Boards of Pharmacy® (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online. Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit medicines were estimated to exceed $75 billion last year – an increase of

September 22, 2011 - Even Famous Faces Have an Advil® Story to Share

(BUSINESS WIRE)--After a day on the tennis court with his doubles partner and wife, Joy, Regis Philbin takes Advil® to relieve the pain that comes from a long match. Just like millions of Americans who rely on Advil® to relieve their tough pain, Regis and Joy have real stories to tell about how Advil® helps them keep doing what they love. The Philbins are the first famous faces to join real Advil® users who share their Advil® stories.

September 21, 2011 - New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia

(BUSINESS WIRE)--Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September 21-24 in Washington, D.C. BZA/CE is being developed by Pfizer for the

September 19, 2011 - Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.

(BUSINESS WIRE)--NEW YORK

September 12, 2011 - Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any

September 12, 2011 - Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer Congress

(BUSINESS WIRE)--Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer’s renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT® (sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 – 27, 2011

September 8, 2011 - Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China

(BUSINESS WIRE)--MADISON, N.J.

September 8, 2011 - Introducing ProNutrients™, A New Line Of Dietary Supplements From The Makers Of Centrum

(BUSINESS WIRE)--Pfizer Consumer Healthcare, makers of Centrum® multivitamins, announced today the launch of ProNutrients™, a line of supplements from the most trusted multivitamin brand helping to increase confidence in supplementing and make nutrition possible. ProNutrients is a new line of dietary supplements launched by the makers of Centrum multivitamins, and is formulated to naturally work with a multivitamin. The line

September 7, 2011 - Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that nine abstracts about tofacitinib (development code CP-690,550), an investigational, novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting, which is being held November 5-9 in Chicago. Detailed Results Being Presented for

September 7, 2011 - Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011 at 9:10 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the Investor Presentations

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.